The estimated Net Worth of Meeta Vyas is at least $390 Tisíc dollars as of 5 September 2014. Mr. Vyas owns over 21,429 units of NanoViricides Inc stock worth over $239,644 and over the last 10 years she sold NNVC stock worth over $0. In addition, she makes $150,469 as Chief Financial Officer at NanoViricides Inc.
Meeta has made over 1 trades of the NanoViricides Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently she bought 21,429 units of NNVC stock worth $75,002 on 5 September 2014.
The largest trade she's ever made was buying 21,429 units of NanoViricides Inc stock on 5 September 2014 worth over $75,002. On average, Meeta trades about 21,429 units every 0 days since 2014. As of 5 September 2014 she still owns at least 147,021 units of NanoViricides Inc stock.
You can see the complete history of Mr. Vyas stock trades at the bottom of the page.
Meeta Vyas serves as Chief Financial Officer of the Company. Ms. Vyas has served as the Company’s Chief Financial Officer since May 13, 2013. Ms. Vyas has over twenty-five years of experience in performance and process improvement of both publicly listed companies and non-revenue producing entities, in areas ranging from Finance and Operations to Strategy and Management. Meeta holds the distinction of being the first Indian woman to be named CEO of a publicly listed U.S. corporation, Signature Brands, Inc., best known for “Mr. Coffee” and “Health-O-Meter” brand products. As CEO, acting COO and Vice Chairman of the Board of Signature Brands, Inc., she was responsible for the development and implementation of a turnaround plan, resulting in Signature’s return to profitability and growth. Later, as the CEO of the World-Wide Fund for Nature - India (WWF-India) and then as a Vice President of the National Audubon Society (USA), both not-for-profit, non-revenue generating entities, Meeta successfully raised unrestricted funding that significantly exceeded annual requirements and also instituted financial processes to measure a variety of performance metrics. Earlier in her career, she was responsible for designing the strategy and initiating the implementation plan for the highly successful information technology outsourcing program at General Electric (“GE”). Also at GE, Ms. Vyas ran GE Appliances’ Range Products business unit having revenues exceeding $1 Billion where her team doubled operating income in less than two years. Prior to that, as a management consultant with McKinsey and Company, she served publicly listed companies in chemicals, industrial, and technology markets, primarily focusing on growth strategies, valuations, post-merger integrations, and logistics operations. Ms. Vyas holds a MBA in Finance from Columbia University’s Graduate School of Business, and a SB in Chemical Engineering from the Massachusetts Institute of Technology.
As the Chief Financial Officer of NanoViricides Inc, the total compensation of Meeta Vyas at NanoViricides Inc is $150,469. There are 2 executives at NanoViricides Inc getting paid more, with Anil Diwan having the highest compensation of $589,038.
Meeta Vyas is 62, she's been the Chief Financial Officer of NanoViricides Inc since 2015. There are 3 older and 3 younger executives at NanoViricides Inc. The oldest executive at NanoViricides Inc is Stanley Glick, 85, who is the Independent Director.
Meeta's mailing address filed with the SEC is C/O NANOVIRICIDES, INC., 135 WOOD STREET, SUITE 205, WEST HAVEN, CT, 06516.
Over the last 15 years, insiders at NanoViricides Inc have traded over $1,608,110 worth of NanoViricides Inc stock and bought 1,581,444 units worth $2,879,162 . The most active insiders traders include Milton Boniuk, Anil Diwan a Pharma, Inc. Theracour. On average, NanoViricides Inc executives and independent directors trade stock every 77 days with the average trade being worth of $126,113. The most recent stock trade was executed by Milton Boniuk on 11 November 2015, trading 25,000 units of NNVC stock currently worth $30,000.
nanoviricides, inc., a nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. its products pipeline includes herpecide dermal topical and eye drops for the treatment of shingles, phn, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and herpecide intraocular injection for viral acute retinal necrosis. the company also develops flucide broad-spectrum anti-influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; nanoviricide eye drops for viral diseases of the external eye; denguecide for treatment of all types of dengue viruses; and hivcide that is an escape-resistant anti-hiv nanoviricide. in addition, it is also involved in research and development of other nanoviricides drug projects for treatment of different viruses and indications; and herpecide program expansion drug projects for different herpes viruses for different indications. nanovir
NanoViricides Inc executives and other stock owners filed with the SEC include: